NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership

Background: The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in tumor biopsies from patients (pts) with refractory solid tumors or lymphomas. NCI-MATCH opened in 8/2015, and a protocol-specified pause in screening for inte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2016-12, Vol.69, p.S137-S137
Hauptverfasser:	Chen, A, Conley, B, Hamilton, S, Williams, M, O'Dwyer, P, Arteaga, C, Gray, R, McShane, L, Li, S, Rubinstein, L, Patton, D, Sazali, K, Zwiebel, J, Mitchell, E, Smith, M.L, Dragaud, D, Little, R, Comis, R, Abrams, J, Flaherty, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Biopsy Breast cancer Cancer therapies Clinical trials Colorectal cancer Communities Endometrium Esophagus Head Hematology, Oncology and Palliative Medicine Lung cancer Lymphoma Medical research MLH1 protein Molecular chains MSH2 protein Mutation Neck Pancreas Prostate Prostate cancer PTEN protein Solid tumors Therapy Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in tumor biopsies from patients (pts) with refractory solid tumors or lymphomas. NCI-MATCH opened in 8/2015, and a protocol-specified pause in screening for interim analysis occurred in 11/2015. The trial reopened on 5/31/16 with revisions based on this analysis. Fourteen new targeted treatments were added (total 24 arms). Other changes include accepting biopsies 1 line of treatment or for which no standard of treatment is known, ECOG PS-1, acceptable organ function. Pts are either biopsied or have tissue available for analysis
ISSN:	0959-8049 1879-0852
DOI:	10.1016/S0959-8049(16)33006-4